Loading...
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmac...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7591087/ https://ncbi.nlm.nih.gov/pubmed/33122892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S275336 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|